Alembic Pharmaceuticals Limited (APLLTD) Stock Forecast & Price Target

Compare

2 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

APLLTD Analyst Ratings

Hold

0 Buy

1 Hold

0 Sell

Based on 1 analysts giving stock ratings to

Alembic

Pharmaceuticals Limited

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

APLLTD Stock 12 Month Forecast

Average Price Target

₹915.00

▼(-1.64% Downside)

Based on 1 Wall Street analysts offering 12 month price targets for Alembic Pharmaceuticals Limited in the last 3 months. The average price target is ₹915.00 with a high forecast of ₹915.00 and a low forecast of ₹915.00. The average price target represents a -1.64% change from the last price of ₹930.30.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"734":"₹734","845":"₹845","956":"₹956","1067":"₹1,067","1178":"₹1,178"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":915,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹915.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":915,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹915.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":915,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹915.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[734,845,956,1067,1178],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,904.2,905.0307692307692,905.8615384615385,906.6923076923077,907.5230769230769,908.3538461538462,909.1846153846154,910.0153846153846,910.8461538461538,911.6769230769231,912.5076923076923,913.3384615384615,914.1692307692308,{"y":915,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,904.2,905.0307692307692,905.8615384615385,906.6923076923077,907.5230769230769,908.3538461538462,909.1846153846154,910.0153846153846,910.8461538461538,911.6769230769231,912.5076923076923,913.3384615384615,914.1692307692308,{"y":915,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,904.2,905.0307692307692,905.8615384615385,906.6923076923077,907.5230769230769,908.3538461538462,909.1846153846154,910.0153846153846,910.8461538461538,911.6769230769231,912.5076923076923,913.3384615384615,914.1692307692308,{"y":915,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1177.4,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1116.38,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1090.32,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1036.86,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":910.02,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":735.65,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":887.71,"date":1743465600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":866.8,"date":1746057600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":866.8,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1003.48,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":958.05,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":941.25,"date":1756684800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":904.2,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target₹915.00

Average Price Target₹915.00

Lowest Price Target₹915.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Damayanti Kerai

HSBC

₹910→₹915

Hold

-1.64%

Downside

Reiterated

10/14/25

HSBC Remains a Hold on Alembic Pharmaceuticals Limited (APLLTD)HSBC analyst Damayanti Kerai raised the price target on Alembic Pharmaceuticals (ALPM:IN) to INR915.00 (from INR910.00) while maintaining a Hold rating.

Abdulkader Puranwala

ICICI Securities

₹885→₹900

Hold

-3.26%

Downside

Reiterated

08/06/25

ICICI Securities Remains a Hold on Alembic Pharmaceuticals Limited (APLLTD)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Damayanti Kerai

HSBC

₹910→₹915

Hold

-1.64%

Downside

Reiterated

10/14/25

Abdulkader Puranwala

ICICI Securities

₹885→₹900

Hold

-3.26%

Downside

Reiterated

08/06/25

ICICI Securities Remains a Hold on Alembic Pharmaceuticals Limited (APLLTD)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

APLLTD Analyst Recommendation Trends

Rating

May 25

Jul 25

Aug 25

Sep 25

Oct 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, APLLTD has received 0 Buy Ratings, 10 Hold Ratings, and 0 Sell Ratings. APLLTD average Analyst price target in the past 3 months is 915.00.

Each month's total comprises the sum of three months' worth of ratings.

APLLTD Financial Forecast

APLLTD Earnings Forecast

Next quarter’s earnings estimate for APLLTD is ₹8.30 with a range of ₹6.80 to ₹9.20. The previous quarter’s EPS was ₹9.40. APLLTD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year APLLTD has Performed in-line its overall industry.

APLLTD Sales Forecast

Next quarter’s sales forecast for APLLTD is ₹18.55B with a range of ₹18.47B to ₹18.62B. The previous quarter’s sales results were ₹19.10B. APLLTD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year APLLTD has Performed in-line its overall industry.

APLLTD Stock Forecast FAQ

What is IN:APLLTD’s average 12-month price target, according to analysts?

Based on analyst ratings, Alembic Pharmaceuticals Limited’s 12-month average price target is 915.00.

What is IN:APLLTD’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for IN:APLLTD, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Alembic Pharmaceuticals Limited a Buy, Sell or Hold?

Alembic Pharmaceuticals Limited has a consensus rating of Hold, which is based on 0 buy ratings, 1 hold ratings and 0 sell ratings.

What is Alembic Pharmaceuticals Limited’s share price target?

The average share price target for Alembic Pharmaceuticals Limited is 915.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is ₹915.00 ,and the lowest forecast is ₹915.00. The average share price target represents -1.64% Decrease from the current price of ₹930.3.

What do analysts say about Alembic Pharmaceuticals Limited?

Alembic Pharmaceuticals Limited’s analyst rating consensus is a Hold. This is based on the ratings of 1 Wall Streets Analysts.

How can I buy shares of Alembic Pharmaceuticals Limited?

To buy shares of IN:APLLTD, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Alembic Pharmaceuticals Limited (APLLTD) Stock Forecast & Price Target

APLLTD Analyst Ratings

APLLTD Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

APLLTD Analyst Recommendation Trends

APLLTD Financial Forecast

APLLTD Earnings Forecast

APLLTD Sales Forecast

APLLTD Stock Forecast FAQ

Detailed List of Analyst Forecasts